GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (FRA:9VC) » Definitions » Notes Receivable

ATAI Life Sciences NV (FRA:9VC) Notes Receivable : €0.48 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV Notes Receivable?

ATAI Life Sciences NV's Notes Receivable for the quarter that ended in Mar. 2024 was €0.48 Mil.

ATAI Life Sciences NV's quarterly Notes Receivable declined from Sep. 2023 (€1.42 Mil) to Dec. 2023 (€0.46 Mil) but then increased from Dec. 2023 (€0.46 Mil) to Mar. 2024 (€0.48 Mil).

ATAI Life Sciences NV's annual Notes Receivable declined from Dec. 2021 (€0.81 Mil) to Dec. 2022 (€0.00 Mil) but then increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.46 Mil).


ATAI Life Sciences NV Notes Receivable Historical Data

The historical data trend for ATAI Life Sciences NV's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV Notes Receivable Chart

ATAI Life Sciences NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
7.42 0.19 0.81 - 0.46

ATAI Life Sciences NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.27 8.33 1.42 0.46 0.48

ATAI Life Sciences NV Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


ATAI Life Sciences NV Notes Receivable Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


ATAI Life Sciences NV (FRA:9VC) Business Description

Traded in Other Exchanges
Address
Wallstraße 16, Berlin, BB, DEU, 10179
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

ATAI Life Sciences NV (FRA:9VC) Headlines

No Headlines